The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
A proposed staging system for amyotrophic lateral sclerosis
Open accessAbstract
Amyotrophic lateral sclerosis is a neurodegenerative disorder characterized by progressive loss of upper and lower motor neurons, with a median survival of 2-3 years. Although various phenotypic and research diagnostic classification systems exist and several prognostic models have been generated, there is no staging system. Staging criteria for amyotrophic lateral sclerosis would help to provide a universal and objective measure of disease progression with benefits for patient care, resource allocation, research classifications and clinical trial design. We therefore sought to define easily identified clinical milestones that could be shown to occur at specific points in the disease course, reflect disease progression and impact prognosis and treatment. A tertiary referral centre clinical database was analysed, consisting of 1471 patients with amyotrophic lateral sclerosis seen between 1993 and 2007. Milestones were defined as symptom onset (functional involvement by weakness, wasting, spasticity, dysarthria or dysphagia of one central nervous system region defined as bulbar, upper limb, lower limb or diaphragmatic), diagnosis, functional involvement of a second region, functional involvement of a third region, needing gastrostomy and non-invasive ventilation. Milestone timings were standardized as proportions of time elapsed through the disease course using information from patients who had died by dividing time to a milestone by disease duration. Milestones occurred at predictable proportions of the disease course. Diagnosis occurred at 35% through the disease course, involvement of a second region at 38%, a third region at 61%, need for gastrostomy at 77% and need for non-invasive ventilation at 80%. We therefore propose a simple staging system for amyotrophic lateral sclerosis. Stage 1: symptom onset (involvement of first region); Stage 2A: diagnosis; Stage 2B: involvement of second region; Stage 3: involvement of third region; Stage 4A: need for gastrostomy; and Stage 4B: need for non-invasive ventilation. Validation of this staging system will require further studies in other populations, in population registers and in other clinic databases. The standardized times to milestones may well vary between different studies and populations, although the stages themselves and their meanings are likely to remain unchanged.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis
Brooks, B. R., Miller, R. G., Swash, M., & Munsat, T. L. (2000) · Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders · doi:10.1080/146608200300079536 · Cited by 5,433 · cited 1×
“All patients met the revised El Escorial-Arlie House Criteria (Brooks et al., 2000) for ALS, and also included those with pure lower and upper motor neuron syndromes.”
MethodCedarbaum, J. M., Stambler, N., Malta, E., Fuller, C., Hilt, D., Thurmond, B., & Nakanishi, A. (1999) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(99)00210-5 · Cited by 3,307
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O., Burrell, J. R., & Zoing, M. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61156-7 · Cited by 2,603
Self-citationA Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
Bensimon, G., Lacomblez, L., & Meininger, V. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300901 · Cited by 2,233
Rao, S. V., & Jollis, J. G. (2000) · Mayo Clinic Proceedings · doi:10.4065/75.10.991 · Cited by 2,217
Brooks, B. R. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90191-0 · Cited by 2,140
Joint modelling of longitudinal measurements and event time data
Henderson, R. (2000) · Biostatistics · doi:10.1093/biostatistics/1.4.465 · Cited by 913
Clinical limits of amyotrophic lateral sclerosis.
Mulder, D. W. (1982) · PubMed · Cited by 440
(1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020045014 · Cited by 415
On Construct Validity: Issues of Method and Measurement.
Smith, G. T. (2005) · Psychological Assessment · doi:10.1037/1040-3590.17.4.396 · Cited by 290
Cited by
van Es, M. A., Hardiman, O., Chio, A., Al-Chalabi, A., Pasterkamp, R. J., Veldink, J. H., & van den Berg, L. H. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31287-4 · Cited by 1,298
Self-citationFeldman, E. L., Goutman, S. A., Petri, S., Mazzini, L., Savelieff, M. G., Shaw, P. J., & Sobue, G. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01272-7 · Cited by 1,129
The epidemiology of ALS: a conspiracy of genes, environment and time
Al-Chalabi, A., & Hardiman, O. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.203 · Cited by 894
Self-citationControversies and priorities in amyotrophic lateral sclerosis
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., Ince, P. G., Lin, C., Miller, R. G., Mitsumoto, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70036-x · Cited by 541
Self-citationRecent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis
Goutman, S. A., Hardiman, O., Al-Chalabi, A., Chió, A., Savelieff, M. G., Kiernan, M. C., & Feldman, E. L. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00465-8 · Cited by 493
Self-citationAmyotrophic lateral sclerosis: moving towards a new classification system
Al-Chalabi, A., Hardiman, O., Kiernan, M. C., Chiò, A., Rix-Brooks, B., & van den Berg, L. H. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)30199-5 · Cited by 390
Self-citationFang, T., Al Khleifat, A., Meurgey, J.-H., Jones, A., Leigh, P. N., Bensimon, G., & Al-Chalabi, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30054-1 · Cited by 259
Self-citationALS-specific cognitive and behavior changes associated with advancing disease stage in ALS
Crockford, C., Newton, J., Lonergan, K., Chiwera, T., Booth, T., Chandran, S., Colville, S., Heverin, M., Mays, I., Pal, S., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006317 · Cited by 264
Self-citationALS and other motor neuron diseases
Tiryaki, E., & Horak, H. A. (2014) · Continuum · doi:10.1212/01.con.0000455886.14298.a4 · Cited by 143
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
Ilieva, H., Vullaganti, M., & Kwan, J. (2023) · BMJ · doi:10.1136/bmj-2023-075037 · Cited by 111
What causes amyotrophic lateral sclerosis?
Martin, S., Al Khleifat, A., & Al-Chalabi, A. (2017) · F1000Research · doi:10.12688/f1000research.10476.1 · Cited by 107
Self-citationJanse van Mantgem, M. R., van Eijk, R. P. A., van der Burgh, H. K., Tan, H. H. G., Westeneng, H.-J., van Es, M. A., Veldink, J. H., & van den Berg, L. H. (2020) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2020-322909 · Cited by 98
Diagnostic Delay in Amyotrophic Lateral Sclerosis
Gwathmey, K. G., Corcia, P., McDermott, C. J., Genge, A., Sennfält, S., de Carvalho, M., & Ingre, C. (2023) · European Journal of Neurology · doi:10.1111/ene.15874 · Cited by 76
Health utility decreases with increasing clinical stage in amyotrophic lateral sclerosis
Jones, A. R., Jivraj, N., Balendra, R., Murphy, C., Kelly, J., Thornhill, M., Young, C., Shaw, P. J., Leigh, P. N., Turner, M. R., et al. (2014) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.3109/21678421.2013.872149 · Cited by 35
Self-citationJanse van Mantgem, M. R., van Rheenen, W., Hackeng, A. V., van Es, M. A., Veldink, J. H., van den Berg, L. H., & van Eijk, R. P. A. (2023) · Neurology · doi:10.1212/wnl.0000000000201657 · Cited by 28
Health Utilities and Costs for Motor Neurone Disease
Moore, A., Young, C. A., & Hughes, D. A. (2019) · Value in Health · doi:10.1016/j.jval.2019.05.011 · Cited by 23
Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosis
Hannaford, A., Byth, K., Pavey, N., Henderson, R. D., Mathers, S., Needham, M., Schultz, D., Menon, P., Kiernan, M. C., & Vucic, S. (2023) · Muscle & Nerve · doi:10.1002/mus.27736 · Cited by 16
de Wit, J., Beelen, A., Drossaert, C. H. C., Kolijn, R., van den Berg, L. H., Visser-Meily, J. M. A., & Schröder, C. D. (2018) · BMC Psychology · doi:10.1186/s40359-018-0232-5 · Cited by 12
Antoniadi, A. M., Galvin, M., Heverin, M., Hardiman, O., & Mooney, C. (2021) · Proceedings of the 36th Annual ACM Symposium on Applied Computing · doi:10.1145/3412841.3441940 · Cited by 12
Gould, R. L., Rawlinson, C., Thompson, B., Weeks, K., Gossage-Worrall, R., Cantrill, H., Serfaty, M. A., Graham, C. D., McCracken, L. M., White, D., et al. (2023) · Pilot and Feasibility Studies · doi:10.1186/s40814-023-01354-7 · Cited by 10
“those in stages 4A or 4B of the King’s College London clinical staging system [32], as these are markers of significantly reduced life expectancy and more advanced disease stage (and hence an indicator that participants might not survive the duration of the study); (2) Diagnosis of dementia using standard diagnostic g…”
BackgroundMethodSelf-citationKeetharuth, A. D., Gould, R. L., McDermott, C. J., Thompson, B. J., Rawlinson, C., Bradburn, M., Bursnall, M., Kumar, P., Turton, E. J., Tappenden, P., et al. (2024) · European Journal of Neurology · doi:10.1111/ene.16317 · Cited by 2
Self-citation
Metadata
- Authors
- Roche, J. C., Rojas-Garcia, R., Scott, K. M., Scotton, W., Ellis, C. E., Burman, R., Wijesekera, L., Turner, M. R., Leigh, P. N., Shaw, C. E., & Al-Chalabi, A.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-01-23
- Volume
- 135
- Issue
- 3
- Pages
- 847-852
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2113481412
- Cited by
- 465
- References
- 27
- FWCI
- 9.35
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.